Tackling Antimicrobial Resistance in the Shadow of COVID-19

The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and...

Full description

Saved in:
Bibliographic Details
Published in:mBio 2021-08, Vol.12 (4), p.e0047321-e0047321
Main Author: Patel, Ami
Format: Article
Language:English
Subjects:
AMR
Anti-Bacterial Agents - therapeutic use
antimicrobial resistance
Antimicrobial Stewardship - methods
bacteria
Coinfection - drug therapy
Coinfection - microbiology
Commentary
COVID-19 - pathology
DNA-encoded antibodies
Drug Resistance, Multiple, Bacterial - genetics
gene-encoded antibodies
Gonorrhea - drug therapy
Health Services Accessibility
Humans
Immunology
Microbial Sensitivity Tests
Neisseria gonorrhoeae - drug effects
Neisseria gonorrhoeae - genetics
personalized medicine
Precision Medicine
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in , Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12:e00242-21, 2021, https://doi.org/10.1128/mBio.00242-21) focus on protection against Neisseria gonorrhoeae infection via delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens.
ISSN:2150-7511
2150-7511
DOI:10.1128/mBio.00473-21